Cannabinoids in Autism and Fragile X Syndrome: Value-Based Treatment Revolution Ahead?

  title={Cannabinoids in Autism and Fragile X Syndrome: Value-Based Treatment Revolution Ahead?},
  author={Zoran Milan Pavlovic},
  • Zoran Milan Pavlovic
  • Published 2017
  • Medicine
  • Cannabis has a long history in Central and South Asia, as it was used to produce hemp fibre for rope, clothing and paper, but was also consumed both for recreational and medicinal purposes. The two major neuro active components in cannabis are the psychoactive Δ9-tetrahydro-cannabinol (Δ9-THC) and the non-psychoactive cannabidiol (CBD). Recent years have seen a resurgence in interest in the therapeutic potential of compounds derived from cannabis, due to significant advances in our… CONTINUE READING

    Topics from this paper.


    Publications referenced by this paper.
    Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.
    • 78
    The mGluR theory of fragile X mental retardation
    • 1,358
    • Open Access
    Molecular mechanisms of fragile X syndrome: a twenty-year perspective.
    • 398
    • Highly Influential
    • Open Access
    Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
    • 504
    • Open Access
    Diagnostic and Statistical Manual of Mental Disorders
    • 35,335
    • Open Access
    Atypical location of cannabinoid receptors in white matter areas during rat brain development
    • 141
    • Open Access
    Neuroglial activation and neuroinflammation in the brain of patients with autism
    • 1,498
    • Open Access
    The CB1 Cannabinoid Receptor Is the Major Cannabinoid Receptor at Excitatory Presynaptic Sites in the Hippocampus and Cerebellum
    • 423
    • Open Access
    More surprises lying ahead. The endocannabinoids keep us guessing
    • 76
    • Open Access
    Fragile X and autism: Intertwined at the molecular level leading to targeted treatments
    • 208
    • Open Access